ALAMEDA, Calif., Oct. 24, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (NasdaqGM:AVGN - News), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, today reported financial results for its third quarter ended September 30, 2007. At September 30, 2007, Avigen had approximately $85 million in financial assets, including cash, cash equivalents, and available-for-sale securities and restricted investments, compared with approximately $90 million at June 30, 2007 and $71 million at December 31, 2006. More complete financial results are detailed in the financial tables below.
